Summary

Global Genomics in Cancer Care Market is valued approximately at USD 40.47 billion in 2023 and is anticipated to grow with a remarkable CAGR of more than 15.14% over the forecast period 2024–2032. Genomics in cancer care is rapidly evolving into a cornerstone of precision oncology, enabling clinicians to tailor therapies based on the unique genetic architecture of individual tumors. By leveraging advanced genomic platforms such as next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH), healthcare providers can decipher intricate mutation patterns and chromosomal alterations. These technologies facilitate early detection, risk stratification, and real-time treatment monitoring. The market is experiencing a seismic shift as multi-omic data convergence and AI-powered bioinformatics transform cancer diagnostics from generalized approaches into highly specific molecular targeting paradigms.
The acceleration in genomic testing adoption is propelled by growing cancer prevalence, regulatory support for companion diagnostics, and the increasing availability of targeted therapies that depend on genomic insights. Additionally, major breakthroughs in NGS scalability and cost-effectiveness have catalyzed its integration into routine clinical workflows. Despite these advances, market expansion is somewhat impeded by high infrastructure costs, lack of skilled personnel, and the complex ethical and data privacy considerations surrounding genomic data. Furthermore, disparities in testing access across low- and middle-income regions raise questions about equitable implementation of precision medicine worldwide.
From guiding immunotherapy in lung cancer to identifying BRCA mutations in breast cancer patients, genomics now plays a pivotal role across the oncology continuum. Clinical applications span diagnostic and prognostic testing, treatment selection, and monitoring patient response to therapy. Blood-based liquid biopsies and tissue sampling continue to dominate, while non-invasive approaches such as urine-based genomic profiling are gaining traction due to their convenience and patient compliance. Hospital-based laboratories remain at the forefront of adoption, but commercial diagnostic labs and academic research institutions are becoming equally vital, especially in translational genomics and biomarker discovery.
The genomics value chain is becoming increasingly decentralized with the emergence of portable sequencing tools, cloud-based analytics, and AI-assisted data interpretation platforms that empower even mid-tier hospitals and oncology centers to offer advanced testing. With industry stakeholders coalescing around integrated genomic ecosystems, partnerships between biopharma giants and diagnostics innovators are fueling drug development pipelines. Additionally, government funding programs and public-private collaborations are accelerating research and enabling population-scale genomic screening efforts that hold the potential to reshape public health frameworks.
Regionally, North America commands the largest market share, underpinned by robust infrastructure, leading genomic research institutions, and favorable reimbursement landscapes. The U.S., in particular, is a genomics innovation powerhouse with a rich startup ecosystem and aggressive R&D investments. Europe follows with strong growth from precision medicine initiatives in Germany, the UK, and France. Meanwhile, Asia Pacific is poised for the highest CAGR during the forecast period, driven by rapidly expanding healthcare systems, growing cancer incidence, and government-backed genomics programs across China, India, Japan, and South Korea. Latin America and the Middle East & Africa are also steadily integrating genomics into their cancer care models, aided by international collaborations and technological transfer.
Major market player included in this report are:
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Illumina, Inc.
• Roche Diagnostics
• PerkinElmer, Inc.
• Becton, Dickinson and Company
• Danaher Corporation
• Myriad Genetics, Inc.
• Bio-Techne Corporation
• Merck KGaA
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers
• Genomic Health, Inc.
• Abbott Laboratories
The detailed segments and sub-segment of the market are explained below:
By Technology
• Next-Generation Sequencing (NGS)
• Comparative Genomic Hybridization (CGH)
• Fluorescence In Situ Hybridization (FISH)
By Cancer Type
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
By Application
• Diagnostic Testing
• Prognostic Testing
• Treatment Selection
• Monitoring Response to Therapy
By Sample Type
• Blood
• Tissue
• Urine
By Clinical Setting
• Hospital-Based Laboratories
• Commercial Laboratories
• Research Institutions
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa
Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1. Global Genomics in Cancer Care Market Executive Summary
1.1. Global Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Technology
1.3.2. By Cancer Type
1.3.3. By Application
1.3.4. By Sample Type
1.3.5. By Clinical Setting
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Genomics in Cancer Care Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Genomics in Cancer Care Market Dynamics
3.1. Market Drivers
3.1.1. Rapid Adoption of Precision Oncology Protocols
3.1.2. Declining Cost and Enhanced Throughput of NGS
3.1.3. Favorable Regulatory Support for Companion Diagnostics
3.2. Market Challenges
3.2.1. High Infrastructure and Implementation Costs
3.2.2. Shortage of Skilled Genomic Data Analysts
3.2.3. Complex Data Privacy and Ethical Concerns
3.3. Market Opportunities
3.3.1. Integration of AI-Powered Bioinformatics Platforms
3.3.2. Expansion of Liquid Biopsy and Non-Invasive Sampling
3.3.3. Growth Potential in Emerging Healthcare Markets
Chapter 4. Global Genomics in Cancer Care Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Market Size & Forecasts by Technology 2022–2032
5.1. Segment Dashboard
5.2. Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Next-Generation Sequencing (NGS)
5.2.2. Comparative Genomic Hybridization (CGH)
5.2.3. Fluorescence In Situ Hybridization (FISH)
Chapter 6. Global Market Size & Forecasts by Cancer Type 2022–2032
6.1. Segment Dashboard
6.2. Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Breast Cancer
6.2.2. Lung Cancer
6.2.3. Colorectal Cancer
Chapter 7. Global Market Size & Forecasts by Application 2022–2032
7.1. Segment Dashboard
7.2. Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Diagnostic Testing
7.2.2. Prognostic Testing
7.2.3. Treatment Selection
7.2.4. Monitoring Response to Therapy
Chapter 8. Global Market Size & Forecasts by Sample Type 2022–2032
8.1. Segment Dashboard
8.2. Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Blood
8.2.2. Tissue
8.2.3. Urine
Chapter 9. Global Market Size & Forecasts by Clinical Setting 2022–2032
9.1. Segment Dashboard
9.2. Revenue Trend Analysis, 2022 & 2032 (USD Billion)
9.2.1. Hospital-Based Laboratories
9.2.2. Commercial Laboratories
9.2.3. Research Institutions
Chapter 10. Global Market Size & Forecasts by Region 2022–2032
10.1. North America Market
10.1.1. U.S. Market
10.1.1.1. Technology breakdown, 2022–2032
10.1.1.2. Application breakdown, 2022–2032
10.1.2. Canada Market
10.2. Europe Market
10.2.1. UK Market
10.2.2. Germany Market
10.2.3. France Market
10.2.4. Spain Market
10.2.5. Italy Market
10.2.6. Rest of Europe Market
10.3. Asia Pacific Market
10.3.1. China Market
10.3.2. India Market
10.3.3. Japan Market
10.3.4. Australia Market
10.3.5. South Korea Market
10.3.6. Rest of Asia Pacific Market
10.4. Latin America Market
10.4.1. Brazil Market
10.4.2. Mexico Market
10.4.3. Rest of Latin America Market
10.5. Middle East & Africa Market
10.5.1. Saudi Arabia Market
10.5.2. South Africa Market
10.5.3. Rest of Middle East & Africa Market
Chapter 11. Competitive Intelligence
11.1. Key Company SWOT Analysis
11.1.1. Thermo Fisher Scientific Inc.
11.1.2. QIAGEN N.V.
11.1.3. Illumina, Inc.
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. Thermo Fisher Scientific Inc.
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. QIAGEN N.V.
11.3.3. Illumina, Inc.
11.3.4. Roche Diagnostics
11.3.5. PerkinElmer, Inc.
11.3.6. Becton, Dickinson and Company
11.3.7. Danaher Corporation
11.3.8. Myriad Genetics, Inc.
11.3.9. Bio-Techne Corporation
11.3.10. Merck KGaA
11.3.11. Agilent Technologies, Inc.
11.3.12. Bio-Rad Laboratories, Inc.
11.3.13. Siemens Healthineers
11.3.14. Genomic Health, Inc.
11.3.15. Abbott Laboratories
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes